EP2968531A4 - HIGH PURITY OVARIAN CANCER CANCER STRAINS FOR ACTIVE AUTOLOGOUS IMMUNOTHERAPY - Google Patents

HIGH PURITY OVARIAN CANCER CANCER STRAINS FOR ACTIVE AUTOLOGOUS IMMUNOTHERAPY

Info

Publication number
EP2968531A4
EP2968531A4 EP14778635.4A EP14778635A EP2968531A4 EP 2968531 A4 EP2968531 A4 EP 2968531A4 EP 14778635 A EP14778635 A EP 14778635A EP 2968531 A4 EP2968531 A4 EP 2968531A4
Authority
EP
European Patent Office
Prior art keywords
cancer
high purity
strains
ovarian cancer
autologous immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14778635.4A
Other languages
German (de)
French (fr)
Other versions
EP2968531A1 (en
Inventor
Andrew N Cornforth
Gabriel Nistor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lisata Therapeutics Inc
Original Assignee
NeoStem Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/053850 external-priority patent/WO2014028274A1/en
Application filed by NeoStem Oncology LLC filed Critical NeoStem Oncology LLC
Publication of EP2968531A1 publication Critical patent/EP2968531A1/en
Publication of EP2968531A4 publication Critical patent/EP2968531A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14778635.4A 2013-03-12 2014-03-10 HIGH PURITY OVARIAN CANCER CANCER STRAINS FOR ACTIVE AUTOLOGOUS IMMUNOTHERAPY Withdrawn EP2968531A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778225P 2013-03-12 2013-03-12
PCT/US2013/053850 WO2014028274A1 (en) 2012-08-15 2013-08-06 Rapid method production high purity cancer stem cells and population of high purity cancer stem cells
PCT/US2014/022494 WO2014164464A1 (en) 2013-03-12 2014-03-10 High purity ovarian cancer stem cells for active autologous immune therapy

Publications (2)

Publication Number Publication Date
EP2968531A1 EP2968531A1 (en) 2016-01-20
EP2968531A4 true EP2968531A4 (en) 2016-12-28

Family

ID=51658876

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14778635.4A Withdrawn EP2968531A4 (en) 2013-03-12 2014-03-10 HIGH PURITY OVARIAN CANCER CANCER STRAINS FOR ACTIVE AUTOLOGOUS IMMUNOTHERAPY

Country Status (8)

Country Link
EP (1) EP2968531A4 (en)
JP (1) JP2016512423A (en)
KR (1) KR20150139529A (en)
CN (1) CN105339000A (en)
AU (1) AU2014249346A1 (en)
CA (1) CA2905288A1 (en)
HK (1) HK1220616A1 (en)
WO (1) WO2014164464A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081554A1 (en) * 2014-11-18 2016-05-26 Neostem Oncology, Llc Immunogenic compositions prepared from tumor cells derived from peripheral blood and originating from a solid tumor and their use
US10472599B2 (en) 2015-01-07 2019-11-12 Dana-Farber Cancer Institute, Inc. Microfluidic cell culture of patient-derived tumor cell spheroids
US11464838B2 (en) * 2015-04-01 2022-10-11 Colorado State University Research Foundation Optimized cancer stem cell vaccines
GB201609663D0 (en) * 2016-06-02 2016-07-20 Stemtek Therapeutics Sl Methods for producing cancer stem cell spheroids
EP3600425A4 (en) 2017-03-31 2020-12-23 Dana-Farber Cancer Institute, Inc. METHOD OF EVALUATION OF TUMOR CELL SPHEROIDS USING A THREE DIMENSIONAL MICROFLUIDIC CELL CULTURE DEVICE
CN110623982B (en) * 2019-09-23 2023-04-25 四川大学华西医院 3D-EMT immune active preparation of ovarian surface epithelial cells and its preparation and application
CN112618712A (en) * 2021-01-21 2021-04-09 武汉轻工大学 Adjuvant containing vimentin and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206286A1 (en) * 2006-09-26 2008-08-28 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US20110313229A1 (en) * 2008-07-24 2011-12-22 Kiminobu Sugaya Therapy Targeting Cancer Stem Cells
WO2012167101A1 (en) * 2011-06-03 2012-12-06 The General Hospital Corporation Ovarian cancer stem cells and methods of isolation and uses thereof
WO2014127276A1 (en) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Ovarian cancer vaccines and vaccination methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067408A2 (en) * 2006-11-28 2008-06-05 Cedars-Sinai Medical Center Method of isolating and propagating stem cells from benign tumors
EP2190481B1 (en) * 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
WO2010124498A1 (en) * 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine
CN101560496A (en) * 2009-04-30 2009-10-21 北京弘润天源生物技术有限公司 Dendritic cell carried by tumor stem cell antigen and subjected to tolerance screening, preparation method and application thereof, kit and vaccine comprising dendritic cell
CN102770530A (en) * 2009-11-05 2012-11-07 斯隆-凯特林癌症研究院 Catenae: serosal cancer stem cells
CA2882095A1 (en) * 2012-08-15 2014-02-20 Andrew CORNFORTH Rapid method production high purity cancer stem cells and population of high purity cancer stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206286A1 (en) * 2006-09-26 2008-08-28 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US20110313229A1 (en) * 2008-07-24 2011-12-22 Kiminobu Sugaya Therapy Targeting Cancer Stem Cells
WO2012167101A1 (en) * 2011-06-03 2012-12-06 The General Hospital Corporation Ovarian cancer stem cells and methods of isolation and uses thereof
WO2014127276A1 (en) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Ovarian cancer vaccines and vaccination methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GORH V ET AL: "Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 102, no. 18, 3 May 2005 (2005-05-03), pages 6461 - 6466, XP008109619, ISSN: 0027-8424, DOI: 10.1073/PNAS.0501953102 *
LOVELAND B E ET AL: "Mannan-MUC1-Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 12, no. 3, 1 February 2006 (2006-02-01), pages 869 - 877, XP008102879, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-1574 *
PONNUSAMY MOORTHY P ET AL: "Ovarian cancer: emerging concept on cancer stem cells", JOURNAL OF OVARIAN RESEARCH, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. 1, 12 October 2008 (2008-10-12), pages 4, XP021046393, ISSN: 1757-2215, DOI: 10.1186/1757-2215-1-4 *
SANTIN A D ET AL: "IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8+ CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 183, 1 January 2000 (2000-01-01), pages 601 - 609, XP001010219, ISSN: 0002-9378, DOI: 10.1067/MOB.2000.107097 *
See also references of WO2014164464A1 *

Also Published As

Publication number Publication date
HK1220616A1 (en) 2017-05-12
AU2014249346A8 (en) 2015-10-15
EP2968531A1 (en) 2016-01-20
CA2905288A1 (en) 2014-10-09
CN105339000A (en) 2016-02-17
KR20150139529A (en) 2015-12-11
AU2014249346A1 (en) 2015-10-01
WO2014164464A1 (en) 2014-10-09
JP2016512423A (en) 2016-04-28

Similar Documents

Publication Publication Date Title
EP3079707A4 (en) Immunotherapy of cancer
IL245725A0 (en) Method of engineering chemotherapy drug resistant t-cells for immunotherapy
EP3090066A4 (en) Determinants of cancer response to immunotherapy
HRP20190460T1 (en) PROCEDURE FOR THE PRODUCTION OF DIRECTORY ENDOTHELIC STATION BY DIRECT DIFFERENTIATION
HUE046414T2 (en) Process for the production of tagatose
PT3083694T (en) Caninized murine anti-canine pd-1 antibodies
EP3192305A4 (en) Fast wifi to lte handover
DK3164414T3 (en) Antibodies to IL-15
EP2948531A4 (en) Compositions of biomass materials for refining
ZA201509334B (en) Improved process for production of monoclonal antibodies
EP2968531A4 (en) HIGH PURITY OVARIAN CANCER CANCER STRAINS FOR ACTIVE AUTOLOGOUS IMMUNOTHERAPY
DK3010352T3 (en) METHOD OF PREPARING FEED ADDITION
EP3135671A4 (en) Novel crystal of tetracyclic compound
EP3291821A4 (en) DENDRITIC CELL IMMUNOTHERAPY
ZA201604296B (en) Synthesis of zsm-48 crystals
EP2966053A4 (en) 2-FLUOROBUTANE OF HIGH PURITY
EP3052630A4 (en) Recombinant microorganism for improved production of fine chemicals
FR3006316B1 (en) COMPOSITION OF POLYARYLENE-ETHER-KETONE-KETONE POWDERS SUITABLE FOR LASER SINTERING
EP3080273A4 (en) Recombinant microorganism for improved production of fine chemicals
EP3003372A4 (en) Inhibitors of complement factor h
SG11201604701PA (en) Novel anti-agglomerants for polyisobutylene production
EP3123173A4 (en) Methods for suppressing cancer by inhibition of tmcc3
EP3011013A4 (en) Methods for treatment of ovarian cancer
EP3039894A4 (en) Zeroconf profile transferring to enable fast roaming
GB201303491D0 (en) Culture of leukemia initiating cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101ALI20161124BHEP

Ipc: A61K 38/19 20060101ALI20161124BHEP

Ipc: A61K 39/395 20060101ALI20161124BHEP

Ipc: A61K 35/13 20150101ALI20161124BHEP

Ipc: A61K 35/15 20150101ALI20161124BHEP

Ipc: A61K 35/12 20060101AFI20161124BHEP

Ipc: A61K 39/00 20060101ALI20161124BHEP

Ipc: A61K 39/39 20060101ALI20161124BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220616

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CALADRIUS BIOSCIENCES, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191001

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1220616

Country of ref document: HK